Quinacrine hydrochloride also has the 4-amino quinoline radical but has, in addition, a benzene ring; it is classified as an acridine compound. The 4-amino quinoline radical is present in all antimalarial compounds shown to be effective in the treatment of lupus erythematosus (LE) (Figure). Plaquenil frontal fibrosing alopecia Chloroquine storage Methotrexate and plaquenil side effects Wart plaquenil One of the key goals of the Lupus Foundation of America Foundation is to ensure people with lupus have access to the care and treatments they need. Recently, access to a few vital treatments has been challenging to obtain, specifically access to quinacrine, hydroxychloroquine, and Benlysta®. In. Lupus erythematosus panniculitis LEP is an unusual clinical variant of lupus erythematosus LE in which the cutaneous inflammatory reaction occurs primarily in the deeper corium. The common clinical features of LEP includes asymptomatic, firm, sharply defined nodules. Lupus panniculitis, or lupus profundus, is a variant of lupus erythematosus that primarily affects subcutaneous fat. In nearly all cases there are deep, erythematous plaques and nodules, and some ulcers, which usually involve the proximal extremities, trunk, breasts, buttocks, and face. Its superiority over quinine was established during World War II, when it became the official drug for the treatment of malaria. Quinacrine was introduced for malaria therapy in 1930. Quinacrine and hydroxychloroquine lupus profundus Drug spotlight on hydroxychloroquine Lupus Foundation of., Lupus Panniculitis Treated by a Combination Therapy of. How does plaquenil work for rheumatoid arthritis Cutaneous lupus erythematosus CLE is an autoimmune, inflammatory skin disease seen in patients with or without systemic lupus erythematosus SLE. The management of CLE includes treatment and prevention of lesions, as well as routine assessment for systemic disease. Treatment options include both topical and systemic therapies. Treatment of Cutaneous Lupus - PubMed Central PMC. Lupus panniculitis lupus profundus. Quinacrine in the treatment of cutaneous lupus.. Quinacrine in the treatment of Cutaneous Lupus Erythematosus Practical Aspects and a Case Series 57 A quinacrine preparation in combination with another antimalarial agent chloroquine or hydroxychloroquine was subsequently marketed for the treatment of discoid lupus. 2 At the end of the 1970s, however, this preparation, along with many other. Abstract. Background Although the benefit of antimalarials in the treatment of cutaneous LE is well established, the effect of combined hydroxychloroquine and quinacrine treatment in systemic lupus erythematosus with major organ involvement remains underappreciated. Patients Six active SLE patients SLEDAI score 5 points. Hydroxychloroquine and chloroquine phosphate have shown beneficial effects in treating discoid lupus erythematosus DLE. Additionally, The antimalarial drugs may prevent the development of systemic lupus erythematosus SLE in patients with DLE, and they might decrease the risk of cardiovascular disease. Alternative therapies, anecdotal reports, and small, open-label trials as reported by.